Plasma renin activity and aldosterone concentration in dogs with acquired portosystemic collaterals.
canine
chronic hepatitis
portal hypertension
primary hypoplasia of the portal vein
renin-angiotensin-aldosterone system
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
19
06
2019
accepted:
29
10
2019
pubmed:
16
11
2019
medline:
22
10
2020
entrez:
16
11
2019
Statut:
ppublish
Résumé
The renin-angiotensin-aldosterone system (RAAS) is activated in humans with portal hypertension (PH) associated with liver disease. However, involvement of RAAS in dogs with intrahepatic PH is not clear. To measure plasma renin activity (PRA) and plasma aldosterone concentration (PAC) in dogs with PH (chronic hepatitis [CH] and primary hypoplasia of the portal vein [PHPV]), dogs with extrahepatic congenital portosystemic shunt (EH-CPSS), and healthy dogs and to determine whether the RAAS is activated in dogs with PH. Twenty-seven dogs with acquired portosystemic collaterals (APSCs; 15 dogs with CH, 12 dogs with PHPV), 9 dogs with EH-CPSS, and 10 healthy dogs. Retrospective study. Plasma renin activity and PAC were measured by radioimmunoassay. Plasma renin activity was significantly higher in the CH group (median, 4.4 ng/mL/h) than in the EH-CPSS (median, 1.0 ng/mL/h; P < .01) and the healthy (median, 1.1 ng/mL/h; P < .01) groups. No significant differences were found between the PHPV group (median, 2.2 ng/mL/h) and other groups. Plasma aldosterone concentration was significantly higher in the CH (median, 111.0 pg/mL) and PHPV (median, 89.5 pg/mL) groups than in the EH-CPSS (median, 1.0 pg/mL; P < .001, P < .01, respectively) and healthy (median, 14.5 pg/mL; P < .001, P < .05, respectively) groups. Activation of the RAAS contributes to the pathophysiology of intrahepatic PH in dogs, suggesting that spironolactone may not only be effective for the treatment of ascites but also for the suppression of intrahepatic PH.
Sections du résumé
BACKGROUND
BACKGROUND
The renin-angiotensin-aldosterone system (RAAS) is activated in humans with portal hypertension (PH) associated with liver disease. However, involvement of RAAS in dogs with intrahepatic PH is not clear.
OBJECTIVE
OBJECTIVE
To measure plasma renin activity (PRA) and plasma aldosterone concentration (PAC) in dogs with PH (chronic hepatitis [CH] and primary hypoplasia of the portal vein [PHPV]), dogs with extrahepatic congenital portosystemic shunt (EH-CPSS), and healthy dogs and to determine whether the RAAS is activated in dogs with PH.
ANIMALS
METHODS
Twenty-seven dogs with acquired portosystemic collaterals (APSCs; 15 dogs with CH, 12 dogs with PHPV), 9 dogs with EH-CPSS, and 10 healthy dogs.
METHODS
METHODS
Retrospective study. Plasma renin activity and PAC were measured by radioimmunoassay.
RESULTS
RESULTS
Plasma renin activity was significantly higher in the CH group (median, 4.4 ng/mL/h) than in the EH-CPSS (median, 1.0 ng/mL/h; P < .01) and the healthy (median, 1.1 ng/mL/h; P < .01) groups. No significant differences were found between the PHPV group (median, 2.2 ng/mL/h) and other groups. Plasma aldosterone concentration was significantly higher in the CH (median, 111.0 pg/mL) and PHPV (median, 89.5 pg/mL) groups than in the EH-CPSS (median, 1.0 pg/mL; P < .001, P < .01, respectively) and healthy (median, 14.5 pg/mL; P < .001, P < .05, respectively) groups.
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
Activation of the RAAS contributes to the pathophysiology of intrahepatic PH in dogs, suggesting that spironolactone may not only be effective for the treatment of ascites but also for the suppression of intrahepatic PH.
Identifiants
pubmed: 31729111
doi: 10.1111/jvim.15661
pmc: PMC6979274
doi:
Substances chimiques
Aldosterone
4964P6T9RB
Renin
EC 3.4.23.15
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-144Informations de copyright
© 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Références
Liver Int. 2005 Dec;25(6):1079-90
pubmed: 16343056
Science. 1988 Oct 28;242(4878):583-5
pubmed: 2845584
J Vet Intern Med. 2016 Mar-Apr;30(2):566-73
pubmed: 26812988
Ann Intern Med. 2009 Jun 2;150(11):776-83
pubmed: 19487712
Gastroenterology. 1980 Jan;78(1):92-9
pubmed: 7350041
Br J Pharmacol. 2009 Nov;158(5):1366-74
pubmed: 19785655
J Vet Intern Med. 2017 May;31(3):764-769
pubmed: 28295621
J Hepatol. 2010 Aug;53(2):273-82
pubmed: 20570385
J Vet Intern Med. 2018 Jan;32(1):26-41
pubmed: 29194760
Dig Dis Sci. 2011 Jul;56(7):2160-5
pubmed: 21290180
Vet Pathol. 2011 Jul;48(4):839-45
pubmed: 21118800
J Vet Sci. 2016 Dec 30;17(4):555-561
pubmed: 27297414
J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S93-5
pubmed: 17567477
J Vet Intern Med. 2017 Sep;31(5):1382-1387
pubmed: 28804949
J Vet Intern Med. 2011 Mar-Apr;25(2):169-86
pubmed: 21382073
J Vet Med Sci. 2010 Jan;72(1):13-8
pubmed: 19893284
Am J Vet Res. 2007 Oct;68(10):1058-63
pubmed: 17916010
J Vet Intern Med. 2019 Mar;33(2):363-382
pubmed: 30806496
J Gastroenterol Hepatol. 2017 Jan;32(1):184-190
pubmed: 27164413
J Vet Med Sci. 2012 Oct;74(10):1299-302
pubmed: 23123767
J Small Anim Pract. 1995 Dec;36(12):521-8
pubmed: 8926720
Am J Med. 1979 May;66(5):804-10
pubmed: 443256
Can J Vet Res. 2008 Oct;72(5):428-31
pubmed: 19086375
Hepatology. 1994 May;19(5):1095-9
pubmed: 8175131
J Vet Intern Med. 2009 Jan-Feb;23(1):63-6
pubmed: 19175722
J Vet Intern Med. 2020 Jan;34(1):139-144
pubmed: 31729111
Eur J Clin Invest. 2008 Dec;38(12):939-44
pubmed: 19021719
Domest Anim Endocrinol. 1995 Jan;12(1):13-24
pubmed: 7621676
Am J Physiol. 1977 Dec;233(6):F586-92
pubmed: 596456
J Vet Intern Med. 2009 Jan-Feb;23(1):72-80
pubmed: 19175724